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Abstract
Genome-wide transcription data of utero-placental tissue has been used to identify altered gene expression associated with
preeclampsia (PE). As many women with PE deliver preterm, there is often a difference in gestational age between PE
women and healthy pregnant controls. This may pose a potential bias since gestational age has been shown to dramatically
influence gene expression in utero-placental tissue. By pooling data from three genome-wide transcription studies of the
maternal-fetal interface, we have evaluated the relative effect of gestational age and PE on gene expression. A total of
18,180 transcripts were evaluated in 49 PE cases and 105 controls, with gestational age ranging from week 14 to 42. A total
of 22 transcripts were associated with PE, whereas 92 transcripts with gestational age (nominal P value ,1.51*1026,
Bonferroni adjusted P value ,0.05). Our results indicate that gestational age has a great influence on gene expression both
in normal and PE-complicated pregnancies. This effect might introduce serious bias in data analyses and needs to be
carefully assessed in future genome-wide transcription studies.
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Introduction
Preeclampsia (PE) is one of the leading causes of perinatal
mortality and deaths of pregnant women worldwide [1,2]. PE is a
pregnancy-specific disorder, diagnosed by de novo onset of
hypertension and proteinuria in the latter half of pregnancy [2–
4]. To date, there are few reliable predictive tests or any effective
treatment available, except delivery of the baby and the placenta.
Consequently, PE accounts for approximately 20% of all preterm
births [5].
The aetiology of PE is not completely understood, but it is
generally considered that disturbed interactions between the
invading (fetal) trophoblasts and maternal cells causing defective
trophoblast invasion are important pathophysiological events.
The subsequent impaired spiral artery remodelling and reduced
placental perfusion is proposed to create oxidative stress and a
release of inflammatory factors into the maternal circulation,
causing overt PE [6]. Gene expression analyses may provide
further insight in mechanisms of disease and function as
preventive, predictive or therapeutic measures. As the molecular
mechanisms behind impaired trophoblast invasion are prefer-
entially reflected at the maternal-fetal interface, attempts to
identify aberrant gene expression associated with preeclamptic
pregnancies at this site have been made. So far, a number of
genome-wide transcription analyses of decidual and placental
bed tissue have been performed using a limited number of
samples [7–9]. Findings in these studies have been inconsistent,
probably reflecting lack of power in each individual study in
combination with the complexity of the disease.
Women with PE often deliver preterm, due to medical
indications or the condition itself. Transcriptional comparisons
of gene expression in utero-placental tissue from women with
PE and women with normal pregnancies are therefore often
hampered by relatively large differences in gestational age. It
has been shown that gene expression in utero-placental tissue
differs dramatically over gestation [10,11]. However, most
studies aiming to identify altered utero-placental expression in
PE have failed to properly assess changes in transcription levels
caused by such differences in gestational age.
In this study, we have pooled data from three different
genome-wide transcription studies [8,9,11] of tissue from the
maternal-fetal interface to assess differential gene expression
associated with both PE and gestational age. This study is the
first to include both variables (PE and gestational age), but also
the first to combine data from different genome-wide platforms
to analyse transcription profiles. In addition, with 154 samples
analysed, this is so far the largest study performed to identify
differences in expression patterns at the maternal-fetal interface.
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Materials and Methods
Microarray Datasets
In this study, we have utilised three publicly available gene
expression datasets from tissue from the maternal-fetal interface
(Table 1). The first dataset consist of analyses of basal plate
biopsies from 36 second- and third trimester singleton pregnancies,
including elective surgical terminations and normal, uncomplicat-
ed term pregnancies [11]. None of these 36 samples were from
women with pregnancies complicated by PE, fetal anomalies,
hypertension, diabetes, infections or other significant maternal
health issues. The dataset is available at the Gene Expression
Omnibus (www.ncbi.nlm.nih.gov/geo/), accession no. GSE5999.
The second dataset consists of 23 basal plate biopsies from women
who developed severe PE (n = 12) or had preterm labour (n = 11)
[9]. Approximately one third of the cases with preterm labour
resulted from cervical insufficiency, and 5 of the PE pregnancies
were complicated by fetal growth restriction. Pregnancies
complicated by fetal anomalies, premature rupture of the
membranes, infections, diabetes, autoimmune diseases or preg-
nancies with multiple gestations were excluded. The dataset is
available at Gene Expression Omnibus (www.ncbi.nlm.nih.gov/
geo/), accession no. GSE14722. The third dataset consists of 95
decidua basalis samples from women who developed PE (n = 37)
and women with normal, uncomplicated term pregnancies (n = 58)
[8]. Among the 37 PE cases, 30 had severe PE or PE complicated
by small for gestational age (SGA) and seven cases had mild PE
not complicated by SGA. Pregnancies with multiple gestations, or
fetal and placental anomalies (such as placenta accreta, placenta
membranacea, placentas from fetuses with chromosomal anom-
alies or developmental anomalies, or macroscopic and microscopic
signs of infection) were excluded. The dataset is available via
ArrayExpress (www.ebi.ac.uk/microarray-as/ae/), accession no.
E-TABM-682. The criteria to diagnose PE as well as severe PE in
dataset #2 and #3 were similar [12,13]. All data used for this
study have been retrieved from www.ncbi.nlm.nih.gov/geo/or
www.ebi.ac.uk/microarray-as/ae/, and no additional ethical
approvals were obtained. A more comprehensive description of
the tissue sampling and study population characteristics can be
found in the original papers for the respective studies [8,9,11].
Probe-mapping and Construction of Probe Pairs
between Microarray Platforms
The transcription data that the three studies used in this work
originate from has been produced on two different microarray
platforms. Dataset #1 and #2 were analysed on Affymetrix HG-
U133A&B GeneChips (Affymetrix, Santa Clara, CA, USA)
including 44,928 probesets, and dataset #3 was analysed on
Illumina HumanWG-6 v2 Expression BeadChips (Illumina Inc.,
San Diego, CA, USA) including 48,095 probes. Affymetrix
interrogates mRNA expression using a panel of different 25mer
probes per transcript (probesets), whereas Illumina uses multiple,
identical 50mer probes per transcript. Both platforms provide
probe annotations, but since the sequence of the human genome is
constantly updated, these annotations do not always match the
latest updated sequence [14]. Having accurate knowledge of which
transcripts the probes and probesets are measuring is essential to
ensure accurate biological interpretation of the results in
downstream analyses. Therefore, probes and probesets from the
two platforms were remapped to Ensembl transcript predictions
using the available Ensembl annotation for expression microarrays
(Ensembl release 57). This Ensembl annotation was produced by
first aligning the probe sequences to the corresponding genome
sequence (Ensembl release 57), using the exonerate alignment tool
[15]. A default of one base pair mismatch was permitted between
the probe and the genome sequence assembly. Probes that
matched at 100 or more locations (e.g. suspected Alu repeats) were
discarded. The remaining probes or probesets were associated
with Ensembl transcript predictions. For Affymetrix probesets, it
was required that .50% of the probes matched a given transcript
sequence. This mapping procedure is described in more detail at
the Ensembl webpage (www.ensembl.org/info/docs/
microarray_probe_set_mapping.html). For the current study,
Illumina-Affymetrix probe pairs were constructed if an Affymetrix
probeset and an Illumina probe mapped to the same Ensembl
transcript. This resulted in multiple probe pairs from some
transcripts. E.g., if two different Affymetrix probesets (A1 and A2)
and two Illumina probes (I1 and I2) mapped to the same
transcript, this resulted in four possible probe pairs (A1–I1, A1–I2,
A2–I1 and A2–I2).
Pre-processing of Microarray Data
All pre-processing procedures were performed using the open
source software R, available via www.bioconductor.org. Affyme-
trix gene expression values from dataset #1 and #2 were
imported into R and extracted using the Robust Multichip
Average (RMA) method [16] implemented in the affy R library.
Illumina gene expression values from dataset #3 were imported
and extracted using the lumi R library. Both methods for extracting
expression values included quantile normalisation. Next, tran-
scription values were inverse normal transformed, for each dataset
separately, to obtain perfect normally distributed values where the
mean is set to zero and standard deviation to one, as described
previously [17]. Briefly, transcription values for all probes were
first inverse normal transformed for each individual separately to
adjust for variation between samples (e.g. RNA quantity). Second,
Table 1. Descriptives of the three dataset used in this study.
Dataset
Number of
samples
Preeclampsia
(PE)
Number of
samples
Non-PE (NP)
Mean gestational
age PE, weeks
(min, max)
Mean gestational
age NP, weeks
(min, max) Microarray platform
Number of
probes/
probesets
#1 [11] 2nd trimester, n = 27
3rd trimester, n = 9
19.3 (14.0, 24.0)
38.6 (37.0, 40.0)
Affymetrix, HG-U133A&B
GeneChip
44,928
#2 [9] 3rd trimester,
n = 12
3rd trimester, n = 11 32.1 (24.1, 37.6) 31.0 (24.7, 36.6) Affymetrix, HG-U133A&B
GeneChip
44,928
#3 [8] 3rd trimester,
n = 37
3rd trimester, n = 58 31.9 (25.0, 39.0) 38.7 (37.0, 42.0) Illumina, HumanWG-6 v2
Expression Beadchip
48,095
doi:10.1371/journal.pone.0069848.t001
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the transcription values for all individuals within each substudy
were inverse normal transformed for each probe, to adjust for
variation between probes (e.g. probe specificity). This normalisa-
tion procedure produces comparable transcription values across
individuals and transcripts (independent of RNA quality, tissue
sampling method and platform etc.).
Statistical Analyses of Microarray Data
The normalised transcription values from the three datasets
were pooled and analysed using the moderated t-test implemented
in limma R library [18,19], available via the bioconductor project
(www.bioconductor.org). First, the transcription values were fitted
to a linear model with PE-status and gestational age as covariables,
as well as a factor with values (1, 2 or 3) to separate the three
studies. This factor allows the mean expression level for each
transcript to differ between studies, which is expected if the
samples included in three studies differed in terms of gestational
age, different rate of PE incidence and sampling methods. Second,
an empirical Bayesian method [18] was applied to the fitted model
object. To correct for multiple testing, a Bonferroni adjusted P
value of 0.05/33,088 (number of Illumina-Affymetrix probe
pairs) = 1.51*1026 was used as significance threshold in all
analyses. To evaluate if the majority of the transcripts were
regulated by gestational age or PE-status, the proportion of non-
differentially expressed genes were estimated, as described
previously [20]. In addition to the variables described above, we
assessed the interaction between PE and gestational age by
including an interaction term (PE*gestational age) in the linear
model.
Linear Model Fitting for Gestational Age
Gene expression levels are known to vary over gestation, but
whether this relationship is linear throughout pregnancy is not
known. In a previous study of gestational age-related transcrip-
tional changes at the maternal-fetal interface [11] (dataset #1,
Table 1), gestational age was categorised as either mid-gestation or
term, whereas we have assumed a linear relationship between
gestational age and transcription levels. To evaluate if these two
methods for estimating gestational age effects provided similar
results, we first reanalysed dataset #1 using the moderated t-test
two times. The first time we used gestational age as a continuous
variable, and the second time we dichotomised gestational age into
mid-gestation and term. We then compared the log2 fold change
(log2FC) values between analyses for each transcript.
Ingenuity Pathway Analyses
We used Ingenuity Pathway Analysis (IPA) v7.5 (Ingenuity
Systems, Redwood City, CA, USA) to study the biological function
of the genes that were differentially expressed in association with
PE or gestational age. Fischer’s exact test was used to investigate if
any biological function were over-represented among these genes.
No adjustment for multiple testing was done in the IPA analyses.
Concordance with Previous Studies
To investigate whether our assessment of PE- and gestational
age-related transcripts was similar to the individual three sub-
studies included, we compared our results to those previously
published [8,9,11]. However, as the three sub-studies originally
were analysed using different methods and settings, results were
Figure 1. A comparison of two methods for identifying gestational age-related transcripts; using gestational age as a linear
variable age or dichotomising it to midgestation and term. The correlation coefficient between the log2 fold change (log2FC) values in the
two methods (Pearson’s product-moment correlation coefficient) is 0.94 (P value ,2.2*10216).
doi:10.1371/journal.pone.0069848.g001
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not directly comparable. We therefore reanalysed each dataset
(#1–#3) separately using the moderated t-test, and compared
these results to the results when the three datasets were pooled. For
each transcript, the log2FCs corresponding to PE and gestational
age were compared across datasets. In addition, we compared the
top 100 most significant results (ranked by P value) for PE- and
gestational age-related transcripts between the datasets.
Results
Study Group Characteristics and Microarray Datasets
Genome-wide transcription data from 154 tissue samples from
the maternal-fetal interface, originating from three different
datasets (Table 1), were used in this work. A total of 105 non-
preeclamptic (NP) controls with gestational age ranging between
week 14 to 42 in addition to 49 PE cases with gestational age
ranging from week 24 to 39 were included in the analyses (Table 1).
Probe Remapping and Construction of Probe Pairs
Between Microarray Platforms
A total of 33,088 Illumina-Affymetrix probe pairs (correspond-
ing to 25,903 Affymetrix probesets and 17,933 Illumina probes)
were identified by remapping probes from Affymetrix HG-
U133A&B GeneChips and Illumina HumanWG-6 v2 BeadChips
to Ensembl transcript predictions. These 33,088 probe pairs target
18,180 Ensembl transcripts representing 14,678 different HGNC
(HUGO (Human Genome Organisation) Gene Nomenclature
Committee) genes.
Linear Model Fitting for Gestational Age
The comparison of the two different methods for identifying
gestational age-related transcripts (using gestational age as a
quantitative variable versus dichotomising it to mid-gestation
and term) showed that these two methods gave similar results
(Figure 1, Pearson’s product-moment correlation coefficient
0.94, P,2.2*10216). Consequently, we conclude that gestational
age can be used as a linear variable as well as being
dichotomised into mid-gestation and term. Using a linear
relationship allows for interpolation of the effect of gestational
age throughout the total range of our data and compensates for
the discrepancy in gestational age between datasets (Figure 2).
PE- and Gestational Age-related Transcripts
Of the 33,088 Illumina-Affymetrix probe pairs analysed, 29
were differentially expressed between PE and NP after
correction for multiple testing (Table 2). Together, these probe
pairs represents 22 different transcripts. In contrast, as many as
174 probe pairs, representing 92 different transcripts, were
significantly associated with gestational age (Table 3). For the
most significant observations, there were clear changes in
transcription levels associated with either PE or gestational
age (Figure 3, Figure S1 and S2). We did not detect any
significant interactions between PE and gestational age. Two
transcripts were associated with both PE-status and gestational
age; fibroblast activation protein (FAP) and corticotropin
releasing hormone (CRH). FAP was down-regulated in PE and
decreased expression over gestation, whereas CRH was up-
regulated in PE and increased expression over gestation. The
Figure 2. Distribution of gestational ages in the three datasets. The figure shows the median, 1st and 3rd quantile, range of the data and
outliers. The grey boxes represent the preeclamptic cases (PE) and white boxes represent normal pregnancies (NP).
doi:10.1371/journal.pone.0069848.g002
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estimated fraction of differentially expressed transcripts [20] was
49% for gestational age and 30% for PE. Since transcription
values for the three datasets were standardised for each
transcript prior to merging, all between-study-effects such as
tissue source would be excluded. We did not allow for
interaction between the study/tissue source and the effect of
PE or gestational age on transcription values. To evaluate if the
inclusion of controls with very low gestational age affected the
results, we performed the same analyses excluding controls
(n = 15) with gestational age ,20 weeks. The results were very
similar to the original results with a correlation between the –
log10 (P values) for PE-associated transcripts of R = 0.96, and
for the gestational age-associated transcripts r = 0.88. However,
removing these 15 individuals decreased the number of
significantly associated transcripts from 174 to 72 for gestational
age, and from 29 to 18 for PE. Still, the ranking of the P values
for the two subanalyses were the same (as indicated by the high
correlation coefficients), and the decrease in number of
significant findings most likely reflects the decrease in power
by decreasing the sample size. Similarly, to test if the inclusion
of cases with mild PE influenced the results, we performed the
same analyses by excluding the seven cases with mild PE from
dataset #3. These results are also very similar to the primary
results with a correlation coefficient between the log2FC for PE-
associated transcripts of R = 0.99.
Ingenuity Pathway Analyses
IPA analysis of the 22 PE-associated transcripts (Table 2)
identified in our analyses demonstrated an over-representation of
biological functions such as cellular growth and proliferation, cell
death, endocrine system disorders and metabolic disease (Table 4).
IPA analysis of the 92 gestational age-associated transcripts
(Table 3) demonstrated over-representation of the biological
functions cellular assembly and organisation, tissue development,
cellular movement, cardiovascular system development and
function, cellular growth and proliferation, connective tissue
development, cell-to-cell signalling and interaction, and cell cycle
(Table 5).
Table 2. Preeclampsia-associated transcripts (Bonferroni corrected P,0.05, nominal P,1.52*1026).
Gene symbol Description Fold change P value Illumina probe id Affymetrix probe id
AMD1 adenosylmethionine decarboxylase 1 2.20 3.6E-08 ILMN_1788462 201196_s_at
AMD1 adenosylmethionine decarboxylase 1 2.00 1.2E-06 ILMN_1788462 201197_at
ANGPTL2 angiopoietin-like 2 22.34 2.4E-09 ILMN_1772612 213001_at
ANGPTL2 angiopoietin-like 2 22.03 7.3E-07 ILMN_1772612 213004_at
CALML4 calmodulin-like 4 22.00 1.2E-06 ILMN_1652389 221879_at
CAMSAP1L1 calmodulin regulated spectrin-associated
protein 1-like 1
2.11 1.6E-07 ILMN_1792660 212763_at
CAMSAP1L1 calmodulin regulated spectrin-associated
protein 1-like 1
2.01 1.1E-06 ILMN_1792660 212765_at
COL6A1 collagen, type VI, alpha 1 22.06 4.1E-07 ILMN_1732151 213428_s_at
CRH corticotropin releasing hormone 2.02 8.5E-07 ILMN_1668035 205629_s_at
EGFR epidermal growth factor receptor 2.06 3.9E-07 ILMN_1798975 201984_s_at
FAP fibroblast activation protein, alpha 21.99 1.5E-06 ILMN_1741468 209955_s_at
FIBIN fin bud initiation factor homolog 22.17 6.0E-08 ILMN_1716247 226769_at
KIAA1919 KIAA1919 2.00 1.2E-06 ILMN_1691916 232139_s_at
KIAA1919 KIAA1919 2.09 2.4E-07 ILMN_1691916 238828_at
LIMCH1 LIM and calponin homology domains 1 2.07 3.6E-07 ILMN_1664138 212325_at
LIMCH1 LIM and calponin homology domains 1 2.18 5.0E-08 ILMN_1664138 212327_at
LIMCH1 LIM and calponin homology domains 1 2.20 3.3E-08 ILMN_1664138 212328_at
MAF v-maf musculoaponeurotic fibrosarcoma
oncogene homolog
22.05 4.5E-07 ILMN_1719543 206363_at
NDFIP2 Nedd4 family interacting protein 2 2.09 2.5E-07 ILMN_1677396 224799_at
NDFIP2 Nedd4 family interacting protein 2 1.99 1.4E-06 ILMN_1677396 224801_at
NEBL nebulette 2.01 1.1E-06 ILMN_1808824 207279_s_at
PLAC9 placenta-specific 9 21.99 1.4E-06 ILMN_1790859 227419_x_at
PMP22 peripheral myelin protein 22 22.00 1.3E-06 ILMN_1785646 210139_s_at
RARRES2 retinoic acid receptor responder 2 22.12 1.3E-07 ILMN_1811873 209496_at
SCRN1 secernin 1 22.04 5.2E-07 ILMN_1756439 201462_at
SERPINF1 serpin peptidase inhibitor, clade F, member 1 22.07 3.3E-07 ILMN_1685078 202283_at
SLC39A8 solute carrier family 39, member 8 2.04 6.1E-07 ILMN_1695316 219869_s_at
SRPX sushi-repeat-containing protein, X-linked 22.18 4.5E-08 ILMN_1709486 204955_at
TP53INP2 tumor protein p53 inducible nuclear protein 2 22.10 2.0E-07 ILMN_1686906 224836_at
doi:10.1371/journal.pone.0069848.t002
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Concordance with Previous Studies
Since the number of significant transcripts in the previous
publications of the included datasets was very limited when
applying a stringent threshold for multiple testing (Bonferroni), no
rigorously comparison between datasets could be performed.
However, lists of transcripts/probes that were claimed to be
differentially expressed in the three original studies are included
(Tables S1–S3). A comparison of our reanalysis of dataset #1 with
36 NP samples and our analyses of all three datasets combined
with 154 samples showed that the log2FC values for gestational
age-associated transcripts were highly correlated (Pearson’s
product-moment correlation coefficient 0.94, P,2.2*10216). In
addition, the top 100 transcripts from the reanalysis of dataset #1
were all nominally significant (P,0.05) in our analysis of the
pooled datasets and 20 transcripts were shared between the top
100 transcripts from dataset #1 and the pooled analyses.
Comparing our separate reanalyses of dataset #2 and #3 (with
12 or 37 PE samples and 11 or 58 NP samples, respectively) with
our analysis of the pooled dataset (49 PE and 105 NP), we found
that the correlation between the log2FC values for PE in dataset
#2 and the pooled dataset (Pearson’s product-moment correlation
coefficient 0.57, P,2.2*10216) were similar to the correlation
between the PE log2FC values for dataset #3 and the pooled
dataset (Pearson’s product-moment correlation coefficient 0.71,
P,2.2*10216). For the sub-analysis of PE-associated transcripts in
dataset #2, 78 of the top 100 transcripts were nominally
significant (P,0.05) in our pooled analyses of PE-associated
transcripts, but only two of these were significant in the pooled
analyses after correction for multiple testing and four transcripts
were shared between the top 100 transcripts from dataset #2 and
the pooled analyses. For the reanalysis of dataset #3, 93 of the top
100 transcripts were nominally significant (P,0.05) in our total
analysis, of which nine were significant in the pooled dataset after
correction for multiple testing. Seven transcripts were shared
between the top 100 transcripts from dataset #3 and the pooled
analyses. The correlation between dataset #2 and #3 log2FC
values from the PE-associated transcripts was low (Pearson’s
product-moment correlation coefficient 0.04, P,1.04*10213).
This is not surprising, since none of the PE-associated transcripts
in dataset #2 and only two in dataset #2 were significant after
correcting for multiple testing (Bonferroni).
Discussion
In this work, we have pooled data from three different genome-
wide transcription analyses of samples from the maternal-fetal
interface to generate a dataset consisting of 154 samples. To the
best of our knowledge, this is the largest dataset used to assess
changes in transcription levels associated with either PE or
gestational age. A total of 92 gestational age-related and 22 PE-
associated transcripts were identified. These numbers by them-
selves indicates that a large fraction of variance in transcription
levels at the maternal-fetal interface can be attributed to
gestational age rather than PE-status. The large sample size
achieved by pooling datasets from three different studies enabled
us to apply a stringent significance threshold (Bonferroni adjusted
P values) in order to minimise the probability of false positives.
Using Bonferroni cut-off of 0.05 corresponds to false discovery rate
(FDR) cut-offs of 2.8*1024 for gestational age and 1.7*1023 for PE
[21]. Previous genome-wide transcription studies on PE have not
used such stringent threshold for significance, and those findings
should be interpreted with care. In accordance with this, only few
PE- or gestational age- associated transcripts from previous
publications have been replicated in others or our study.
The most significant finding among the PE-associated tran-
scripts was the down-regulation (P= 2.43*1029, .2 fold down-
regulated) of angiopoietin-like 2 (ANGPTL2). The ANGPTL2
protein is a secreted glycoprotein with homology to the
angiopoietins, which are important angiogenic factors. Although
the angiopoietin-like proteins do not bind to the angiopoietin
receptor, they are believed to play a role in angiogenesis via
induction of endothelial cell sprouting in blood vessels [22]. We
also observed a down-regulation of RARRES2 (retinoic acid
receptor responder 2, also called chemerin) among the PE-
associated transcripts. It was recently demonstrated that chemerin
could induce angiogenesis in vitro [23,24]. Down-regulation of
these angiogenic factors may be linked to the pathogenesis of PE
through abnormal vascular morphology, as placentas from women
with severe PE, especially in combination with fetal growth
restriction, are characterised by decreased capillary volume and
surface area [25].
The expression of CRH and FAP were significantly associated
with both PE-status and gestational age. While the expression of
CRH increased with gestational age and was up-regulated in PE,
Figure 3. Variation in transcription values for three selected transcripts depending on gestational age. Transcription values
(normalised) are plotted for different gestational ages (weeks). The red points represent preeclamptic (PE) pregnancies and blue points normal
pregnancies (NP). The lines are the estimated regression lines for gestational age (red line for PE, blue line for NP), separated by the regression
coefficient for PE-status. In Figure A, the transcription level is significantly associated with both PE-status and gestational age. In B, the transcription
level is associated with gestational age only, and in C with PE-status only.
doi:10.1371/journal.pone.0069848.g003
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Table 3. Gestational age-associated transcripts (Bonferroni corrected P,0.05, nominal P,1.52*1026).
Gene symbol Description
Fold change
(per week) P value Illumina probe id Affymetrix probe id
ADAMTS5 ADAM metallopeptidase with thrombospondin
type 1 motif, 5
21.057 3.6E-07 ILMN_1671747 219935_at
ADAMTS5 ADAM metallopeptidase with thrombospondin
type 1 motif, 5
21.057 3.7E-07 ILMN_1671747 229357_at
ADAMTS5 ADAM metallopeptidase with thrombospondin
type 1 motif, 5
21.055 9.0E-07 ILMN_1671747 235368_at
ANGPT2 angiopoietin 2 21.059 2.0E-07 ILMN_1774207 205572_at
ANGPT2 angiopoietin 2 21.056 7.6E-07 ILMN_1774207 211148_s_at
ANGPT2 angiopoietin 2 21.058 2.6E-07 ILMN_1774207 236034_at
ANGPT2 angiopoietin 2 21.058 2.3E-07 ILMN_1774207 237261_at
ANKRD50 ankyrin repeat domain 50 21.055 9.6E-07 ILMN_1729342 225731_at
ANKRD50 ankyrin repeat domain 50 21.057 5.1E-07 ILMN_1729342 225735_at
APH1B anterior pharynx defective 1 homolog B (C. elegans) 21.055 9.3E-07 ILMN_1862217 226358_at
ASPH aspartate beta-hydroxylase -21.055 1.0E-06 ILMN_1693771 224996_at
ASPH aspartate beta-hydroxylase 21.055 1.0E-06 ILMN_1739719 224996_at
ASS1 argininosuccinate synthase 1 21.058 2.9E-07 ILMN_1688234 207076_s_at
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 21.055 9.2E-07 ILMN_1736862 201243_s_at
ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 21.055 1.0E-06 ILMN_1664772 212136_at
ATP6V1E1 ATPase, H+ transporting, lysosomal 31kDa, V1
subunit E1
1.055 1.1E-06 ILMN_1798485 208678_at
BCAT1 branched chain amino-acid transaminase 1, cytosolic 21.055 1.2E-06 ILMN_1766169 225285_at
BCAT1 branched chain amino-acid transaminase 1, cytosolic 21.057 5.1E-07 ILMN_1766169 226517_at
BMP6 bone morphogenetic protein 6 1.064 1.7E-08 ILMN_1747650 206176_at
C1orf115 chromosome 1 open reading frame 115 1.055 1.1E-06 ILMN_1674817 218546_at
C20orf194 chromosome 20 open reading frame 194 21.056 7.1E-07 ILMN_1673005 225825_at
C3orf58 chromosome 3 open reading frame 58 21.056 8.0E-07 ILMN_1797372 226464_at
CAB39L calcium binding protein 39-like 21.058 2.8E-07 ILMN_1730529 225914_s_at
CAB39L calcium binding protein 39-like 21.057 5.3E-07 ILMN_1660815 225914_s_at
CAB39L calcium binding protein 39-like 1.060 1.3E-07 ILMN_1665449 226028_at
CAPN6 calpain 6 1.057 3.5E-07 ILMN_1782654 202965_s_at
CCNYL1 cyclin Y-like 1 21.055 1.1E-06 ILMN_1810069 227280_s_at
CD200 CD200 molecule 1.065 1.2E-08 ILMN_1706722 209582_s_at
CD200 CD200 molecule 1.063 3.0E-08 ILMN_1706722 209583_s_at
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 21.059 1.5E-07 ILMN_1672611 207172_s_at
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 21.066 6.5E-09 ILMN_1672611 207173_x_at
CEACAM1 carcinoembryonic antigen-related cell adhesion
molecule 1 (biliary glycoprotein)
1.059 1.5E-07 ILMN_1716815 209498_at
CEACAM1 carcinoembryonic antigen-related cell adhesion
molecule 1 (biliary glycoprotein)
1.057 4.2E-07 ILMN_1664330 209498_at
CEBPB CCAAT/enhancer binding protein (C/EBP), beta 1.056 8.0E-07 ILMN_1693014 212501_at
CETP cholesteryl ester transfer protein, plasma 1.059 1.8E-07 ILMN_1681882 206210_s_at
CITED2 Cbp/p300-interacting transactivator, with
Glu/Asp-rich carboxy-terminal domain, 2
21.060 1.2E-07 ILMN_1663092 209357_at
CMPK1 cytidine monophosphate (UMP-CMP) kinase 1,
cytosolic
21.057 3.9E-07 ILMN_1738642 217870_s_at
COL14A1 collagen, type XIV, alpha 1 21.055 9.5E-07 ILMN_1786598 212865_s_at
COL1A2 collagen, type I, alpha 2 21.057 3.6E-07 ILMN_1785272 202403_s_at
COL1A2 collagen, type XXI, alpha 1 21.060 1.1E-07 ILMN_1785272 202404_s_at
COL21A1 collagen, type III, alpha 1 21.063 3.3E-08 ILMN_1732850 208096_s_at
COL3A1 collagen, type III, alpha 1 21.060 1.3E-07 ILMN_1773079 201852_x_at
COL3A1 collagen, type III, alpha 1 21.058 2.3E-07 ILMN_1773079 211161_s_at
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COL3A1 collagen, type III, alpha 1 21.058 3.4E-07 ILMN_1773079 215076_s_at
COL5A1 collagen, type V, alpha 1 21.056 6.7E-07 ILMN_1706505 212489_at
COL5A2 collagen, type V, alpha 2 21.059 1.9E-07 ILMN_1729117 221729_at
COL5A2 collagen, type V, alpha 2 21.055 9.7E-07 ILMN_1729117 221730_at
COL6A3 collagen, type VI, alpha 3 21.065 1.2E-08 ILMN_1706643 201438_at
CRH corticotropin releasing hormone 1.059 2.0E-07 ILMN_1668035 205629_s_at
CTSC cathepsin C 21.059 2.2E-07 ILMN_1792885 225646_at
CTSC cathepsin C 21.056 6.3E-07 ILMN_1689086 225646_at
CUX1 cut-like homeobox 1 21.055 1.2E-06 ILMN_1727603 225221_at
DCN decorin 21.059 1.7E-07 ILMN_1701748 209335_at
DCN decorin 21.058 2.9E-07 ILMN_1768227 209335_at
DCN decorin 21.057 5.1E-07 ILMN_1666672 209335_at
DCN decorin 21.055 9.4E-07 ILMN_1701748 211896_s_at
DEPDC7 DEP domain containing 7 21.057 4.5E-07 ILMN_1718152 228293_at
DUSP1 dual specificity phosphatase 1 1.060 9.7E-08 ILMN_1781285 201041_s_at
EFHD1 EF-hand domain family, member D1 1.055 1.2E-06 ILMN_1779448 209343_at
EHBP1 EH domain binding protein 1 21.056 6.3E-07 ILMN_1803348 212653_s_at
ELOVL6 ELOVL family member 6, elongation of long chain
fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast)
21.058 2.5E-07 ILMN_1700546 204256_at
ERG v-ets erythroblastosis virus E26 oncogene
homolog (avian)
1.054 1.3E-06 ILMN_1768301 213541_s_at
FABP4 fatty acid binding protein 4, adipocyte 1.074 7.1E-11 ILMN_1773006 203980_at
FADS1 fatty acid desaturase 1 21.058 2.5E-07 ILMN_1670134 208962_s_at
FAP fibroblast activation protein, alpha 21.055 1.1E-06 ILMN_1741468 209955_s_at
FBXO42 F-box protein 42 1.057 4.3E-07 ILMN_1756874 221813_at
FKBP14 FK506 binding protein 14, 22 kDa 21.056 8.6E-07 ILMN_1665243 230728_at
FKBP7 FK506 binding protein 7 21.057 4.2E-07 ILMN_1717737 224002_s_at
FNBP1L formin binding protein 1-like 21.058 3.3E-07 ILMN_1754600 215017_s_at
GALNT3 UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 3 (GalNAc-T3)
21.056 8.3E-07 ILMN_1671039 203397_s_at
GAS1 growth arrest-specific 1 21.056 6.6E-07 ILMN_1772910 204457_s_at
GFOD2 glucose-fructose oxidoreductase domain
containing 2
1.055 1.1E-06 ILMN_1744006 221028_s_at
GJA1 gap junction protein, alpha 1, 43kDa 21.062 5.3E-08 ILMN_1727087 201667_at
GLB1 galactosidase, beta 1 21.058 2.5E-07 ILMN_1790862 201576_s_at
GLUL glutamate-ammonia ligase 21.061 8.8E-08 ILMN_1678881 215001_s_at
GLUL glutamate-ammonia ligase 21.056 6.3E-07 ILMN_1653496 215001_s_at
GPSM1 G-protein signaling modulator 1 21.060 9.5E-08 ILMN_1751666 226043_at
GPSM1 G-protein signaling modulator 1 21.056 6.3E-07 ILMN_1709307 226043_at
GPSM1 G-protein signaling modulator 1 21.056 7.1E-07 ILMN_1796392 226043_at
GPX8 glutathione peroxidase 8 (putative) 21.058 2.3E-07 ILMN_1767665 228141_at
HAPLN1 hyaluronan and proteoglycan link protein 1 21.056 6.7E-07 ILMN_1678812 205524_s_at
HBD hemoglobin, delta 1.061 5.5E-08 ILMN_1815527 206834_at
HOMER1 homer homolog 1 (Drosophila) 21.056 7.2E-07 ILMN_1804568 213793_s_at
HOMER1 homer homolog 1 (Drosophila) 21.057 4.5E-07 ILMN_1804568 226651_at
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble 21.061 6.0E-08 ILMN_1696432 201193_at
IL6ST interleukin 6 signal transducer 21.065 9.6E-09 ILMN_1849013 212195_at
IL6ST interleukin 6 signal transducer 21.061 5.8E-08 ILMN_1797861 212195_at
IL6ST interleukin 6 signal transducer 21.059 1.6E-07 ILMN_1746604 212195_at
ITGA1 integrin, alpha 1 21.055 9.8E-07 ILMN_1802411 214660_at
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KCTD12 potassium channel tetramerisation
domain containing 12
21.057 4.7E-07 ILMN_1742332 212192_at
KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic
reticulum protein retention receptor 3
21.056 6.0E-07 ILMN_1713901 204017_at
KIAA1598 KIAA1598 21.055 1.3E-06 ILMN_1805992 221802_s_at
KLF2 Kruppel-like factor 2 (lung) 21.060 1.2E-07 ILMN_1735930 219371_s_at
KREMEN1 kringle containing transmembrane protein 1 1.059 2.1E-07 ILMN_1772697 227250_at
LDLR low density lipoprotein receptor 21.056 8.1E-07 ILMN_1651611 202068_s_at
LGALS3 lectin, galactoside-binding, soluble, 3 21.055 1.2E-06 ILMN_1665479 208949_s_at
LGALS3 lectin, galactoside-binding, soluble, 3 21.061 6.1E-08 ILMN_1747118 208949_s_at
LGALS8 lectin, galactoside-binding, soluble, 8 21.059 1.8E-07 ILMN_1669930 208934_s_at
LGALS8 lectin, galactoside-binding, soluble, 8 1.059 2.1E-07 ILMN_1669930 208936_x_at
LIMA1 LIM domain and actin binding 1 1.056 6.7E-07 ILMN_1704369 217892_s_at
LMO4 LIM domain only 4 21.055 9.4E-07 ILMN_1703487 227155_at
LUM lumican 21.056 7.7E-07 ILMN_1790529 201744_s_at
MAN1A1 mannosidase, alpha, class 1A, member 1 21.056 6.8E-07 ILMN_1742187 221760_at
MCC mutated in colorectal cancers 21.063 3.0E-08 ILMN_1795503 226225_at
MFSD2A major facilitator superfamily domain
containing 2A
21.054 1.5E-06 ILMN_1798284 225316_at
MMRN2 multimerin 2 1.055 1.0E-06 ILMN_1715788 219091_s_at
NAP1L1 nucleosome assembly protein 1-like 1 1.057 4.5E-07 ILMN_1705876 208752_x_at
NAP1L1 nucleosome assembly protein 1-like 1 21.056 6.5E-07 ILMN_1705876 208753_s_at
NAP1L1 nucleosome assembly protein 1-like 1 21.059 2.2E-07 ILMN_1699208 208753_s_at
NAP1L1 nucleosome assembly protein 1-like 1 21.056 7.7E-07 ILMN_1705876 213864_s_at
NAP1L1 nucleosome assembly protein 1-like 1 21.064 1.9E-08 ILMN_1699208 213864_s_at
NDRG2 NDRG family member 2 21.061 7.4E-08 ILMN_1670535 206453_s_at
NID1 nidogen 1 1.055 9.5E-07 ILMN_1674719 202007_at
NID2 nidogen 2 (osteonidogen) 21.060 1.4E-07 ILMN_1698706 204114_at
NPL N-acetylneuraminate pyruvate lyase
(dihydrodipicolinate synthase)
21.062 5.3E-08 ILMN_1782070 221210_s_at
OAT ornithine aminotransferase 21.056 7.8E-07 ILMN_1654441 201599_at
OLA1 Obg-like ATPase 1 21.058 2.4E-07 ILMN_1659820 219293_s_at
OLFML3 olfactomedin-like 3 21.057 4.9E-07 ILMN_1727532 218162_at
PAPLN papilin, proteoglycan-like sulfated
glycoprotein
21.060 9.7E-08 ILMN_1710495 226435_at
PCYOX1 prenylcysteine oxidase 1 21.061 8.3E-08 ILMN_1679725 225274_at
PDGFRA platelet-derived growth factor receptor,
alpha polypeptide
21.055 1.2E-06 ILMN_1681949 203131_at
PDZRN3 PDZ domain containing ring finger 3 21.056 8.5E-07 ILMN_1699552 212915_at
PDZRN3 PDZ domain containing ring finger 3 21.055 1.2E-06 ILMN_1703511 212915_at
PLA2G7 phospholipase A2, group VII (platelet-
activating factor acetylhydrolase, plasma)
21.061 7.4E-08 ILMN_1701195 206214_at
PPL periplakin 1.058 2.4E-07 ILMN_1806030 203407_at
PPP1R14C protein phosphatase 1, regulatory
(inhibitor) subunit 14C
1.056 8.4E-07 ILMN_1664855 226907_at
PTPRB RAB6B, member RAS oncogene family 1.055 1.0E-06 ILMN_1821052 205846_at
RAB6B roundabout, axon guidance receptor,
homolog 1 (Drosophila)
1.059 1.4E-07 ILMN_1752299 225259_at
ROBO1 ribosomal protein, large, P0 21.060 1.1E-07 ILMN_1806790 213194_at
RPLP0 ribosomal protein, large, P0 21.059 1.5E-07 ILMN_1709880 201033_x_at
RPLP0 ribosomal protein, large, P0 21.057 5.3E-07 ILMN_1748471 201033_x_at
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RPLP0 ribosomal protein, large, P0 21.055 9.9E-07 ILMN_1709880 208856_x_at
RPLP0 ribosomal protein, large, P0 21.057 4.2E-07 ILMN_1709880 211720_x_at
RPLP0 ribosomal protein, large, P0 21.055 1.2E-06 ILMN_1709880 211972_x_at
RPS2 ribosomal protein S2, pseudogene 6 21.061 6.4E-08 ILMN_1662982 203107_x_at
RPS2 ribosomal protein S2, pseudogene 6 21.063 2.9E-08 ILMN_1662982 212433_x_at
RPS2 ribosomal protein S2, pseudogene 6 21.061 8.7E-08 ILMN_1709604 212433_x_at
SC4MOL sterol-C4-methyl oxidase-like 21.058 3.0E-07 ILMN_1720889 209146_at
SC4MOL sterol-C4-methyl oxidase-like 21.057 4.8E-07 ILMN_1689842 209146_at
SESTD1 SEC14 and spectrin domains 1 21.059 2.0E-07 ILMN_1782341 226763_at
SLC2A10 solute carrier family 2 (facilitated
glucose transporter), member 10
21.062 4.2E-08 ILMN_1663351 221024_s_at
SLC39A10 solute carrier family 39 (zinc
transporter), member 10
21.055 1.1E-06 ILMN_1656129 225295_at
SMYD3 SET and MYND domain containing 3 21.056 7.8E-07 ILMN_1741954 218788_s_at
SNORA10 small nucleolar RNA, H/ACA box 10 21.059 1.9E-07 ILMN_1709604 203107_x_at
SOAT1 sterol O-acyltransferase 1 21.062 4.8E-08 ILMN_1699100 221561_at
SOAT1 sterol O-acyltransferase 1 21.062 4.1E-08 ILMN_1699100 228479_at
SPP1 secreted phosphoprotein 1 21.059 2.0E-07 ILMN_1651354 209875_s_at
STAT5B signal transducer and activator of
transcription 5B
1.055 1.2E-06 ILMN_1777783 205026_at
STX3 syntaxin 3 1.056 5.9E-07 ILMN_1659544 209238_at
SVIL supervillin 21.054 1.3E-06 ILMN_1671404 202565_s_at
SYNPO synaptopodin 1.057 3.6E-07 ILMN_1711491 202796_at
TCF7L2 transcription factor 7-like 2
(T-cell specific, HMG-box)
21.055 1.1E-06 ILMN_1672486 212759_s_at
TCF7L2 transcription factor 7-like 2
(T-cell specific, HMG-box)
21.059 1.7E-07 ILMN_1672486 212761_at
TCF7L2 transcription factor 7-like 2
(T-cell specific, HMG-box)
21.058 2.6E-07 ILMN_1672486 212762_s_at
TCF7L2 transcription factor 7-like 2
(T-cell specific, HMG-box)
21.063 2.3E-08 ILMN_1672486 216035_x_at
TCF7L2 transcription factor 7-like 2
(T-cell specific, HMG-box)
21.060 1.4E-07 ILMN_1672486 216037_x_at
TMEM150C transmembrane protein 150C 21.056 8.3E-07 ILMN_1797047 229623_at
TPPP3 tubulin polymerization-promoting protein
family member 3
1.057 3.9E-07 ILMN_1797744 218876_at
TTC3L tetratricopeptide repeat domain 3 21.055 9.7E-07 ILMN_1761476 210645_s_at
TUBB tubulin, beta 21.056 6.1E-07 ILMN_1665583 212320_at
TUBB tubulin, beta 21.054 1.4E-06 ILMN_1703692 212320_at
unspecific 21.060 1.1E-07 ILMN_1748471 211720_x_at
unspecific 21.058 3.5E-07 ILMN_1748471 211972_x_at
UQCRH ubiquinol-cytochrome c reductase hinge
protein-like
21.055 1.1E-06 ILMN_1718136 202233_s_at
VCAN versican 21.057 3.6E-07 ILMN_1687301 204619_s_at
VCAN versican 21.058 2.4E-07 ILMN_1687301 204620_s_at
VCAN versican 21.058 2.5E-07 ILMN_1687301 211571_s_at
VCAN versican 21.058 2.3E-07 ILMN_1687301 215646_s_at
WARS tryptophanyl-tRNA synthetase 1.055 1.1E-06 ILMN_1727271 200629_at
WNT5A wingless-type MMTV integration site family,
member 5A
21.054 1.4E-06 ILMN_1800317 213425_at
XPOT exportin, tRNA 21.055 1.3E-06 ILMN_1743711 212160_at
ZFHX3 zinc finger homeobox 3 21.060 1.2E-07 ILMN_1808587 226137_at
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the expression of FAP decreased with gestational age and was
down-regulated in PE. The transcriptional changes of FAP and
CRH are probably linked to both gestational age and PE. During
pregnancy, CRH is produced by decidual and placental tissue [26],
and released into the fetal and maternal circulation. Maternal
plasma CRH levels increase over gestation [27], concurrent with
our observation of CRH among the gestational age-related
transcripts. A further elevation of maternal plasma CRH levels
has been shown in PE compared to normal pregnancies at the
same gestational age [28]. Increased levels of CRH may contribute
to the pathogenesis of PE trough its role in regulation of vascular
resistance and blood flow in utero-placental tissue [29].
Among the transcripts that were up- or down- regulated due to
gestational age, we noted decreased expression of galectin 3
(LGALS3) and increased expression of galectin (LGALS8). Galectins
are highly expressed at the maternal-fetal interface, and regarded
as multifunctional regulators of fundamental cellular processes due
to their capacity to modulate functions such as cell-extracellular
matrix interactions, proliferation, adhesion, and invasion [30].
Galectin 3 is expressed in placental cell columns, but not in
invasive extravillous trophoblasts [31]. The negative correlation
between expression and trophoblast invasiveness is in accordance
with our finding of decreased galectin 3 expression over gestation.
Galectin 8 is expressed by decidual cells, villous and extravillous
trophoblasts [32], but its role is less clearly understood.
The IPA analyses of the 22 PE-associated transcripts demon-
strated an over-representation of genes associated with metabolic
disease (Table 4). PE share several metabolic abnormalities with
cardiovascular diseases and diabetes, and having a PE complicated
pregnancy is associated with increased risk of type 2 diabetes later
in life [33]. This agrees with pregnancy acting as a stress factor
which could reveal a pre-existing disposition to later life metabolic
disease [34]. IPA analysis of the 92 transcripts that were associated
with gestational age revealed an over-representation of genes
involved in cell assembly and organisation, tissue development,
cellular movement, tissue morphology, and connective tissue
development and function (Table 5). These findings are in
agreement with known biological processes taking place at the
maternal-fetal interface during pregnancy, such as trophoblast
proliferation, differentiation, invasion and extracellular matrix
remodelling.
It is important to consider that the data used in our study was
produced on two different microarray platforms, and that tissue
sampling procedures differed between the three sub-studies
included in our dataset. In dataset #1 and #2, basal plate
biopsies were used for transcriptional analyses, whereas in dataset
#3, decidual tissue was collected by vacuum suction of the entire
placental bed. These differences may pose a potential bias, as gene
expression has been shown to differ depending on tissue sampling
site [35]. Inter- and intra-platform reproducibility has been shown
to be good in terms of detecting differentially expressed genes [36–
38]. However, the reproducibility of absolute transcription levels is
poor, and pre-processing is required before comparisons of
transcription values across platforms can be made. To deal with
these limitations, and be able to make both inter- and intra-
platform comparisons of transcription values, we performed
inverse normal transformation. After this transformation, the
distribution of transcription values is assumed equal for all probes,
independent of study, sampling method and platform. However,
PE-status, gestational age and tissue sampling method differed
between studies, and consequently we had to include this as a
factor giving a separate level for each study in the linear regression
model. In our analyses, we exclusively searched for observations
that agreed between datasets, and the limitations mentioned above
will rather reduce the power of identifying differentially expressed
genes than introduce false positive results. Combined with the fact
that our pooled dataset only targets 14,678 genes, and that we are
using a very stringent threshold for significance, our results likely
represent only a small fraction of the total number of transcripts
that are influenced by either PE or gestational age. Had all
samples been collected by the same method and analysed on the
same arrays, it is likely that a much larger number of differentially
expressed transcripts would be identified. In our analyses, we did
not allow for interaction between the study/tissue source and the
effect of PE or gestational age on transcription values. The main
reason for this is that the cause of such interaction would be
impossible to determine (e.g. sampling method, microarray type,
PE heterogeneity etc.). Instead, we focused on identifying shared
effects across studies.
Another limitation in our dataset is the heterogeneity of the PE
group. In dataset #2, all cases had severe PE of which 5 were
complicated by FGR. In dataset #3 30 of 37 cases had severe PE
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ZFP42 zinc finger protein 42 homolog (mouse) 21.054 1.4E-06 ILMN_1751127 243161_x_at
ZKSCAN1 zinc finger with KRAB and SCAN domains 1 21.055 1.0E-06 ILMN_1687567 225935_at
doi:10.1371/journal.pone.0069848.t003
Table 4. Ingenuity Pathway Analysis of preeclampsia-associated transcripts.
Biological functions Genes included P value
Cellular growth and proliferation COL6A1, CRH, EGFR, PMP22, SERPINF1 2.92*102424.40*1022
Cell death CRH, EGFR, FAP, PMP22, SERPINF1 1.28*102321.53*1022
Endocrine system disorders CAMSAP1L1, CRH, EGFR, KIAA1919, LIMCH1, NEBL, PMP22, SCRN1, SERPINF1 2.57*102322.86*1022
Metabolic disease CAMSAP1L1, CRH, KIAA1919, LIMCH1, NEBL, PMP22, SCRN1, SERPINF1 2.30*102322.57*1022
doi:10.1371/journal.pone.0069848.t004
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or PE complicated by SGA, seven had mild PE. We recognise that
this may indicate that some of our PE-associated transcripts may
be linked to SGA pathogenesis or restricted to severe PE, and that
it would have been preferable to use a more homogenous case
group. The sample size of PE cases was too small to allow for any
stratification in the analyses. It is therefore important to consider
that our results might not be generalisable to all kinds of PE.
However, PE is a complex disorder. Classifying individuals into
e.g. severe and mild PE does not necessarily mean that these are
different disorders. Rather, the diagnosis of both mild and severe
PE are combinations of different quantitative characteristics, and
at some pre-defined cut-off, the disorder is regarded as severe. This
means that the underlying causes of PE might be as complex
within the patients with severe PE as between cases with severe
and mild PE. The NP group is also heterogeneous, including
samples from preterm labour without infection (1/3 of these due to
cervical insufficiency), elective terminations (of which the future
pregnancy outcome is unknown), as well as normal pregnant
women. Including cases with preterm labour may have influenced
our results, as this condition with or without infection is likely to
result from some sort of pathology that could result in gene
expression changes. A possible shared pathology between preterm
birth or PE might also result in similar changes in gene expression,
which would reduce our power to identify PE-specific differentially
expressed genes. However, it is almost impossible to match severe
PE cases with regards to gestational age by using completely
healthy individuals, as normal pregnancies in this gestational age
range (week 24–36) are rare. The inclusion of samples with
gestational age ,20 weeks may also have confounded our results,
as the future pregnancy outcome is unknown, and they may have
developed PE later in pregnancy. However, excluding these
samples from the analyses did not change the results, but rather
decreased the power due to the smaller sample size.
Unfortunately, we were not able validate the microarray results,
e.g. through quantitative real-time (qRT-) PCR, for all our
significant findings, mainly due to lack of RNA. However,
validations have previously been performed for a subset of our
genes: ANGPTL2, CRH, TCF7L2, PLA2G7 and TCF7L2 [8,11] with
good results. Even though more comprehensive corroborative
studies might have be useful for verifying the results, there are
many examples where this is not feasible, e.g. due to lack of RNA
[39]. It is also worth considering that microarray data are
generally much more accurate compared to qRT-PCR. For qRT-
PCR, housekeeping genes are assumed to be equally expressed in
all samples, and commonly used for normalisation procedures.
However, it has been shown that the expression of housekeeping
genes vary dramatically between individuals and that the
heritability is as high as 0.56 for some housekeeping genes [17].
Consequently, housekeeping genes are not ideal for internal
standardisation. The normalisation procedure performed for
microarray experiments, based on the average expression level
per individual, is likely to generate more precise estimates.
To our knowledge, this is the first study to simultaneously assess
the effects of gestational age and PE-status on gene expression at
the maternal-fetal interface. We found that a much large number
of transcripts were influenced by gestational age compared to PE
status. Based on this, we strongly recommend that adjustments for
gestational age should be performed in similar studies. The large
sample size achieved by pooling different datasets allowed us to
apply a stringent threshold for significance, which has not been
feasible in most previous studies. The transcripts identified in this
study are likely to be influenced by gestational age or disease
status, or even play a direct role in the development of PE.
Supporting Information
Figure S1 Variation in transcription values depending
on gestational age for all transcripts that were signifi-
cantly associated with preeclampsia (PE). Normalised
transcription values are plotted for different gestational ages
(weeks). The red points represent PE pregnancies and blue points
normal pregnancies (NP). The lines are the estimated regression
lines for gestational age (red line for PE and blue line for NP),
separated by the regression coefficient for PE-status.
(PDF)
Figure S2 Variation in transcription values depending
on gestational age for all transcripts that were signifi-
cantly associated with gestational age. Normalised tran-
scription values are plotted for different gestational ages (weeks).
The red points represent preeclamptic (PE) pregnancies, and blue
points normal pregnancies (NP). The lines are the estimated
regression lines for gestational age (red line for PE and blue line for
NP), separated by the regression coefficient for PE-status.
(PDF)
Table 5. Ingenuity Pathway Analysis of gestational age-associated transcripts.
Biological functions Genes included P value
Cellular assembly and organization COL1A2, COL3A1, COL5A1, COL5A2, LIMA1, VCAN, IL6ST, NID1, LGALS3 1.88*102721.12*1022
Tissue development BMP6, CDH11, CITED2, COL1A2, COL3A1, COL5A1, COL5A2, COL6A3, DCN, ERG,
IL6ST, ITGA1, KLF2, LGALS3, LGALS8, NID1, SVIL, TCF7L2, VCAN, WNT5A, SPP1
3.31*102521.05*1022
Cellular movement BMP6, CDH11, CEACAM1, CITED2, DCN, FAP, GJA1, ITGA1, LGALS3, PDGFRA,
ROBO1, SPP1, TCF7L2, VCAN, WARS, WNT5A
5.35*102521.02*1022
Cardiovascular system development
and function
BMP6, CEACAM1, CITED2, COL1A2, COL3A1, DCN, ITGA1, TCF7L2, WARS, WNT5A 2.82*102422.19*1022
Cellular growth and proliferation BCAT1, BMP6, CDH11, CEACAM1, CEBPB, CITED2, COL6A3, COL14A1, CRH, CTSC,
CUX1, DCN, DUSP1, ERG, FADS1, GAS1, GJA1, GLUL, IL6ST, ITGA1, KLF2, LGALS3,
MCC, NAP1L1, PDGFRA, SOAT1, SPP1, TCF7L2, VCAN, WARS, WNT5A, ZFHX3
4.04*102421.46*1022
Connective tissue development CDH11, COL14A1, IL6ST, PDGFRA, SPP1, TCF7L2, VCAN, WNT5A 1.04*102321.46*1022
Cell-to-cell signaling and interaction BMP6, CD200,CEACAM1,CEBPB, CRH, DCN, ERG, IL6ST, ITGA1, LDLR, LGALS3,
LGALS8, NID1, PDGFRA, SPP1, VCAN, WNT5A
3.96*102321.46*1022
Cell cycle BCAT1, BMP6, CEBPB, CRH, DCN, DUSP1, GJA1, LGALS3 7.35*102321.22*1022
doi:10.1371/journal.pone.0069848.t005
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Table S1 Genes reported as differentially expressed in PE in the
study by Winn et al. [9].
(XLSX)
Table S2 Genes reported as differentially expressed between
between midgestation and term in the study by Winn et al. [11].
(XLSX)
Table S3 Genes reported as differentially expressed in PE in the
study by Loset et al. [8].
(XLSX)
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